NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018

  • Mesa R
  • Jamieson C
  • Bhatia R
  • et al.
N/ACitations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

Cite

CITATION STYLE

APA

Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., … Sundar, H. (2017). NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network, 15(10), 1193–1207. https://doi.org/10.6004/jnccn.2017.0157

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free